Last reviewed · How we verify
RSVpreF 120 µg (rsvpref-120-g)
RSVpreF 120 µg is an investigational vaccine developed by Pfizer Inc. to prevent respiratory syncytial virus (RSV) infection in high-risk infants and young children. The vaccine is designed to elicit a strong immune response against the prefusion form of the RSV F protein, which is crucial for viral entry into host cells. Currently, RSVpreF 120 µg is in clinical trials and has not yet received FDA approval. Early clinical data suggest that the vaccine is generally well-tolerated, with common side effects including injection site reactions, fever, and irritability. Pfizer aims to address the significant unmet need for a preventive measure against RSV, a leading cause of hospitalization in infants.
At a glance
| Generic name | rsvpref-120-g |
|---|---|
| Sponsor | Pfizer |
| Drug class | Recombinant subunit vaccine |
| Target | Prefusion form of the RSV F protein |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Prevention of RSV lower respiratory tract disease in neonates at high risk of RSV disease
- Prevention of RSV lower respiratory tract disease in infants and children at high risk of RSV disease
Pipeline indications
Common side effects
Drug interactions
- Atazanavir
- Cobicistat
- Darunavir
- Efavirenz
- Elvitegravir
- Emtricitabine
- Etravirine
- Indinavir
- Lopinavir
- Nelfinavir
- Ritonavir
- Saquinavir
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RSVpreF 120 µg CI brief — competitive landscape report
- RSVpreF 120 µg updates RSS · CI watch RSS
- Pfizer portfolio CI